iShares Genomics Immunology & Healthcare ETF (IDNA) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Recent news

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
IDNA

ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
IDNA

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
IDNA

Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
IDNA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.36
- MACD 12/26/9
- 0.76
- EMA 9 of MACD
- 1.00
- MACD histogram
- -0.24
- SMA 50
- $38.65
- Price above SMA 50
- EMA 50
- $38.80
- Price above EMA 50
- SMA 200
- $32.06
- Price above SMA 200
- EMA 200
- $32.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
IDNA

ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
IDNA

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
IDNA

Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
IDNA

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up
IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up
IDNA

Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review
Moderna Stock Gains After FDA Accepts Company’s Revised Flu Vaccine Application For Review
IDNA

IDNA: Healthcare Dashboard For February
IDNA: Healthcare Dashboard For February
IDNA

IDNA: Continues To Underperform, But With Long-Term Potential
IDNA: Continues To Underperform, But With Long-Term Potential
IDNA

IDNA: Thematic Biotechnology Index Fund Only Suitable For The Long Run
IDNA: Thematic Biotechnology Index Fund Only Suitable For The Long Run
IDNA

Is This the Most Lucrative Way to Play AI?
Is This the Most Lucrative Way to Play AI?
IDNA
News tone: automated (AI) classification of the article's content, not a price prediction.
About iShares Genomics Immunology & Healthcare ETF
The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. The funds provides access to companies at the forefront of genomics and immunology innovation and aims to provide exposure to global stocks along the full value chain of genomics, immunotherapy and healthcare industries.
Fundamentals
Valuation
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 50.36
- MACD 12/26/9
- 0.76
- EMA 9 of MACD
- 1.00
- MACD histogram
- -0.24
- SMA 50
- $38.65
- Price above SMA 50
- EMA 50
- $38.80
- Price above EMA 50
- SMA 200
- $32.06
- Price above SMA 200
- EMA 200
- $32.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +5.1 | -6.1 | -4.3 | |||||||||
| 2022 | -17.3 | -5.8 | +0.6 | -15.4 | -5.9 | +2.8 | +6.7 | -4.7 | -12.0 | +1.8 | +2.9 | -10.2 |
| 2023 | +7.5 | -11.5 | -2.6 | +0.5 | +1.0 | -3.0 | +3.1 | -3.6 | -10.6 | -8.6 | +12.5 | +9.1 |
| 2024 | -4.7 | +7.5 | -1.5 | -5.2 | +2.9 | -4.0 | +7.1 | +2.7 | +0.9 | -1.3 | +0.9 | -8.0 |
| 2025 | +0.2 | +0.9 | -6.5 | +5.2 | -2.1 | +0.0 | +3.0 | +4.8 | +5.6 | +4.2 | +10.5 | -2.1 |
| 2026 | +8.7 | +7.9 | -6.0 | +0.7 | +1.9 | +15.1 | -3.8 | +21.1 | +6.7 | -2.9 |
Corporate actions
Upcoming
No upcoming corporate actions for IDNA




